drugset
drugset / Trial / NCT05285137

Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects

NCT05285137 ↗

Phase 1 Completed 77 enrolled Cidara Therapeutics Inc. Janssen Pharmaceuticals · collab
RandomizedSequentialQuadruple-blindPrevention

Summary

The purpose of this first-in-human study is to determine the safety and tolerability profile of CD388 Injection, as compared to saline placebo, when administered as a single dose to healthy adult subjects by injection either in the muscle or under the skin.

Timeline

Start
2022-03-14
Primary completion
2023-10-27
Completion
2023-10-27

Drugs

EvaluationDrugModalityDoseRoute
Subject CD388 Other / unclassified 50 mg Intramuscular
Subject CD388 Other / unclassified 150 mg Intramuscular
Subject CD388 Other / unclassified 450 mg Intramuscular
Subject CD388 Other / unclassified 900 mg Intramuscular

Indications

No indication recorded.